AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 mg islatravir
Description: Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
Study NCT00589667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Gemcitabine
Description: Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist.
Study NCT00606489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03480984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Bolus
Description: 6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
Study NCT03480984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: 6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
Study NCT01587248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic
Description: Dissection with harmonic scalpel
Study NCT01587248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocautery
Description: Dissection in modified radical mastectomy
Study NCT03242226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two spectacles
Description: single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
Study NCT03242226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single vision spectacles
Description: Wear single vision spectacle only
Study NCT03776084 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP indication
Study NCT01983007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Description: Performance of high-intensity exercise
Study NCT01983007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Description: Performance of low-intensity exercise
Study NCT03765047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed
Study NCT01479647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 1 mg, single dose
Study NCT04480229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenursing and Counseling
Description: After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
Study NCT00896012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
Study NCT01479647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 10 mg, single dose
Study NCT00671216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Subjects will receive 50 mcg once daily as a single dose
Study NCT00671216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Study NCT00671216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study medication will be inhaled by subjects
Study NCT04258865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO
Study NCT03860350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged Garlic Extract
Study NCT00896012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (sirolimus/rapamycin)
Description: Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
Study NCT00896012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
Study NCT01932788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 4000 IU in gummy form
Description: Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
Study NCT01932788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gummy vitamin
Description: Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
Study NCT03654144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: oral tablets
Study NCT03654144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: oral tablets
Study NCT04039529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENERGY-guided Biopsy
Description: Use of SCENERGY during a lung, liver or kidney biopsy
Study NCT02253043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
Description: PINS Stimulator System
Study NCT03381118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
Study NCT03381118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 40 mg IV infusion on D+5
Study NCT03860350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02005224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LCHF diet and a bout of exercise
Description: Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
Study NCT03722914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzonatate 200 mg
Description: 200 mg/pellet, 1pellet/time, 3times/day
Study NCT04258865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO
Study NCT03722914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank control 0mg
Description: 0 mg/pellet, 1pellet/time, 3times/day
Study NCT03827668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833 alone
Description: In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
Study NCT03827668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 alone
Description: In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
Study NCT03827668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833 together with PF-06651600
Description: In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
Study NCT04191603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONOPOLAR HOOC
Description: COLPOTOMY WITH MONOPOLAR HOOC
Study NCT04191603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLASMAKINETIC BIPOLAR SPATULA
Description: COLPOTOMY WITH BIPOLAR SPATULA
Study NCT04682353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
Study NCT04682353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-subQ Provera
Description: SC injection of 104 mg/0.65 mL
Study NCT03381118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
Study NCT04007913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleCBIT
Description: Eight sessions of individual behavior therapy
Study NCT00418379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR (4M)
Description: 300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
Study NCT00418379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR (2M)
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
Study NCT00418379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00954837 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration
Description: Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
Study NCT04344379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: 200 mg BID per day
Study NCT04344379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 250 mg per day
Study NCT04344379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxychloroquine placebo
Description: 200 mg BID per day
Study NCT04258865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study NCT01479647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 24 mg, single dose
Study NCT02479906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep TMS System
Description: Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
Study NCT02479906 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
Study NCT02301559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises with emphasis on pelvic region
Study NCT03381118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 40 mg IV infusion on D+1
Study NCT03381118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF mobilized HLA-haploidentical donor PBSC
Description: G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
Study NCT03771339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural analgesia
Description: Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
Study NCT01522898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV nodal ablation
Description: Percutaneous catheter ablation of the AV node.
Study NCT01522898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Ventricular Rate Control
Description: Ventricular Rate Control with target ventricular rate of 90 beats per minute.
Study NCT03771339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus Lumborum block
Description: Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
Study NCT03983330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (i-BMI)
Description: The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting.
Study NCT03983330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACILITATION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FACILITATION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INHIBITION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
Study NCT03308565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Adipose derived Mesenchymal Stem Cells
Description: The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
Study NCT03977350 — intervention group
Intervention type: DEVICE
Intervention: EEG monitoring
Description: EEG monitoring under general anesthesia
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INHIBITION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO TAPING
Description: Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
Study NCT04379674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO TAPING
Description: Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
Study NCT02978664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air insufflation during colonoscopy including insertion phase
Study NCT02978664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
Study NCT02947633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection sciatic PNB
Description: Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
Study NCT02947633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous sciatic PNB
Description: Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief.
Study NCT02911220 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: demonstration of genetic mutations causing non-atopic asthma
Description: recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
Study NCT05155423 — intervention group
Intervention type: OTHER
Intervention: mask for immobilization
Description: mask for immobilization
Study NCT05155423 — intervention group
Intervention type: OTHER
Intervention: Elekta BodyFix
Description: Elekta BodyFix
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.